Ocular manifestations of von Hippel-Lindau disease: Clinical and genetic investigations

Transactions of the American Ophthalmological Society

Volumn 103, Issue , 2005, Pages 495-511

  Chew, Mily Ying ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PEGAPTANIB; SEMAXANIB; TRIAMCINOLONE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

CHROMOSOME 3; COMPARATIVE STUDY; DOSE RESPONSE; ENUCLEATION; EYE DISEASE; FAMILY; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETICS; GENOTYPE; HEMANGIOBLASTOMA; HUMAN; LIVER DYSFUNCTION; MICRODISSECTION; MISSENSE MUTATION; MOLECULAR GENETICS; NONSENSE MUTATION; PATHOLOGY; PHENOTYPE; PHYSICIAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; RETINA TUMOR; REVIEW; STROMA CELL; UPREGULATION; VISUAL ACUITY; VISUAL IMPAIRMENT; VISUAL SYSTEM; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLINDNESS; CHILD; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; HEMANGIOBLASTOMA; HIPPEL-LINDAU DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; OPTIC NERVE NEOPLASMS; PROSPECTIVE STUDIES; RETINAL NEOPLASMS; VON HIPPEL-LINDAU DISEASE;

EID: 29944437896     PISSN: 15456110     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. von Hippel E. Uber eine sehr seltene Erkrankung der Netzhaut. Graefes Arch Ophthalmol 1904;59:83-106.
2. Lindau A. Studien ber Kleinbirncysten Bau. Pathogenese und Beziehungen zur Angiomatosis Retinae. Acta Pathol Microbiol Scand 1926;3(suppl 1):1-28.
3. Melmon KL, Rosen SW. Lindau's disease. Review of the literature and study of a large kindred. Am J Med 1964;36:595-617.
4. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-269.
5. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumour suppressor gene. Science 1993;260:1317-1320.
6. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003;361:2059-2067.
7. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-391.
8. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 1995;273:564-570.
9. Richard S, Campello C, Taillandier L, et al. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group. J Intern Med 1998;243:547-553.
10. Richard S, David P, Marsot-Dupuch K, et al. Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurg Rev 2000;23:1-22; discussion 23-24.
11. Wanebo JE, Lonser RR, Glenn GM, et al. The natural history of central nervous system hemangioblastomas in patients with von Hippel-Lindau disease. J Neurosurg 2003;98:82-94.
12. Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000;119:1087-1095.
13. Webster AR, Maher ER, Moore AT. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol 1999;117:371-378.
14. Dollfus H, Massin P, Taupin P, et al. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 2002;43:3067-3074.
15. Welch RB. von Hippel-Lindau disease: the recognition and treatment of early angiomatosis retinae and the use of cryosurgery as an adjunct to therapy. Trans Am Ophthalmol Soc 1970;68:367-424.
16. Singh A, Shields CL, Shields JA. von Hippel-Lindau disease. Surv Ophthalmol 2001;46:117-142.
17. Ridley M, Green J, Johnson G. Retinal angiomatosis: the ocular manifestations of von Hippel-Lindau Disease. Can J Ophthalmol 1986;21:276-283.
18. Maher ER, Iselius L, Yates JR, et al. Von Hippel-Lindau disease: a genetic study. J Med Genet 1991;28:443-447.
19. Neumann HP, Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 1991;337:1052-1054.
20. Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990;77:1151-1163.
21. Neumann HP, Eggert HR, Scheremet R, et al. Central nervous system lesions in von Hippel-Lindau syndrome. J Neurol Neurosurg Psychiatry 1992;55:898-901.
22. Lamiell JM, Salazar FG, Hsia YE. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine 1989;68:1-29.
23. Knudson AG Jr, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet 1972;24:514-532.
24. Knudson AGJ. Genetics of human cancer. Ann Rev Genet 1986;20:231-251.
25. Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumour suppressor protein. Science 1995; 269:1402-1406.
26. Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumour-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A 1997; 94: 2156-2161.
27. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275.
28. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-682.
29. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumour suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-246.
30. Bohling T, Hatva E, Kujala M, et al. Expression of growth factors and growth factor receptors in capillary hemangioblastoma. J Neuropathol Exp Neurol 1996;55:522-527.
31. Reifenberger G, Reifenberger J, Bilzer T, et al. Coexpression of transforming growth factor-alpha and epidermal growth factor receptor in capillary hemangioblastomas of the central nervous system. Am J Pathol 1995;147:245-250.
32. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated, apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-490.
33. Maranchie JK, Afonso A, Albert PS, et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat 2004;23:40-46.
34. Font RL, Ferry AP. The phakomatoses. Int Ophthalmol Clin 1972;12:1-50.
35. Green WR. Retina: capillary hemangioma. In: Spencer WH, ed. Ophthalmic Pathology: An Atlas and Textbook. Philadelphia: WB Saunders; 1996:709-718.
36. Jakobiec FA, Font RL, Johnson FB. Angiomatosis retinae: an ultrastructural study and lipid analyses. Cancer 1976;38:2042-2056.
37. Grossniklaus HE, Thomas JW, Vigneswaran N, et al. Retinal hemangioblastoma: a histologic, immunohistochemical, and ultrastructural evaluation. Ophthalmology 1992;99:140-145.
38. Mottow-Lippa L, Tso MO, Peyman GA, et al. von Hippel angiomatosis. A light, electron microscopic, and immunoperoxidase characterization. Ophthalmology 1983;90:848-855.
39. Vortmeyer AO, Frank S, Jeong SY, et al. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 2003;63:7051-7055.
40. Lubensky IA, Gnarra JR, Bertheau P, et al. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996;149:2089-2094.
41. Vortmeyer AO, Gnarra JR, Emmert-Buck MR, et al. von Hippel-Lindau gene deletion detected in stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 1997;28:540-543.
42. Singh AD, Nouri M, Shields CL, et a;. Treatment of retinal capillary hemangioma. Ophthalmology 2002;109:1799-1806.
43. Annesley WH, Leonard BC, Shields JA, et al. Fifteen year review of treated cases of retinal angiomatosis. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 1977;83:446-453.
44. Rosa RH, Goldberg MF, Green WR. Clinicopathologic correlation of argon laser photocoagulation of retinal angiomas in a patient with von Hippel-Lindau disease followed for more than 20 years. Retina 1996;16:145-156.
45. Schmidt D, Natt E, Neumann HP. Long-term results of laser treatment for retinal angiomatosis in von Hippel-Lindau disease. Eur J Med Res 2000;5:47-58.
46. Garcia-Arumí J, Sararols LH, Cavero L, et al. Therapeutic options for capillary papillary angiomas. Ophthalmology 2000;107:48-54.
47. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, et al. Benefits and complications of photodynamic therapy of papillary capillary angiomas. Ophthalmology 2002;109:1256-1266.
48. Palmer JD, Gragoudas ES. Advances in treatment of retinal angiomas. Int Ophthalmol Clin 1997;37:150-170.
49. McDonald HR, Schatz H, Johnson RN, et al. Vitrectomy in eyes with peripheral retinal angioma associated with traction macular detachment. Ophthalmology 1996;103:329-335.
50. 50 Whitson JT, Welch RB, Green WR. Von Hippel-Lindau disease: case report of a patient with spontaneous regression of a retinal angioma. Retina 1986;6:253-259.
51. Kupersmith MJ, Berenstein A. Visual disturbances in von Hippel-Lindau disease. Ann Ophthalmol 1981;2:195-197.
52. In S, Miyagi J, Kojho N, et al. Intraorbital optic nerve hemangioblastoma with von Hippel-Lindau disease. J Neurosurg 1982;56:426-429.
53. O'Reilly GV, Rumbaugh CL, Bowens M, et al. Supratentorial haemangioblastoma: the diagnostic roles of computed tomography and angiography. Clin Radiol 1980;32:389-392.
54. Nerad JA, Kersten RC, Anderson RL. Hemangioblastoma of the optic nerve. Report of a case and review of literature. Ophthalmology 1988;95;398-402.
55. Rubio A, Meyers SP, Powers JM, et al. Hemangioblastoma of the optic nerve. Hum Pathol 1994;25:1249-1251.
56. Kerr DJ, Scheithauer BW, Miller GM, et al. Hemangioblastoma of the optic nerve: case report. Neurosurgery 1995;36:573-581.
57. Wasenko JJ, Rodziewicz GS. Suprasellar hemangioblastoma in Von Hippel-Lindau disease: a case report. Clin Imaging 2003;27:18-22.
58. Chan CC, Vortmeyer AO, Chew EY, et al. VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol 1999;117:625-630.
59. Aiello LP, George DJ, Cahill MT, et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Ophthalmology 2002;109:1745-1751.
60. Girmens JF, Erginay A, Massin P, et al. Vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 2003;136:194-196.
61. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003;110:979-986.
62. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-346.
63. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473-1480.
64. Nauck M, Karakiulakis G, Perruchoud A, et al. Corticosteriods inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-315.
65. Nauck M, Roth M, Tamm M, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997;16:398-406.